Assessing risk to benefit ratio in antiepileptic drug therapy
Authors:
- Ettore BeghiEBEttore Beghi
- Olivier DulacODOlivier Dulac
- Simon ShorvonSSSimon Shorvon
- Torbjörn TomsonTTTorbjörn Tomson
- 1 August 2000
- journal article
- review article
- Published by Elsevier in Epilepsy Research
- Vol. 41 (2) , 107-139
Abstract
No abstract availableKeywords
This publication has 225 references indexed in Scilit:
- Safety and efficacy of vigabatrin and carbamazepine in ne wly diagnosed epilepsy: a multicentre randomised double-blind studyThe Lancet, 1999
- Is the prophylactic use of antiepileptic drugs in Sturge-Weber syndrome justified?Medical Hypotheses, 1998
- Febrile seizures — treatment and outcomeBrain and Development, 1996
- Efficacy of gabapentin therapy in children with refractory partial seizuresThe Journal of Pediatrics, 1996
- Phenobarbital for Febrile Seizures — Effects on Intelligence and on Seizure RecurrenceNew England Journal of Medicine, 1990
- Discontinuing Antiepileptic DrugsNew England Journal of Medicine, 1988
- Do Seizures in Children Cause Intellectual Deterioration?New England Journal of Medicine, 1986
- Comparison of Carbamazepine, Phenobarbital, Phenytoin, and Primidone in Partial and Secondarily Generalized Tonic–Clonic SeizuresNew England Journal of Medicine, 1985
- Effective short-term diazepam prophylaxis in febrile convulsionsThe Journal of Pediatrics, 1985
- The Prognosis for Seizure Control in Newly Diagnosed EpilepsyNew England Journal of Medicine, 1984